Drug Type Antibody drug conjugate (ADC) |
Synonyms Eribulin/farletuzumab antibody drug conjugate, Farletuzumab/eribulin ADC, FZEC + [2] |
Target |
Mechanism FOLR1 antagonists(Folate receptor alpha antagonists), Tubulin inhibitors |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhasePhase 2 |
First Approval Date- |
Regulation- |
Molecular FormulaC30H42N6O11 |
InChIKeyFPFZTWMOHOCTJK-NVQXNPDNSA-N |
CAS Registry- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Ovarian Cancer | Phase 2 | US | 01 Feb 2023 | |
Ovarian Cancer | Phase 2 | US | 01 Feb 2023 | |
Ovarian Cancer | Phase 2 | JP | 01 Feb 2023 | |
Ovarian Cancer | Phase 2 | JP | 01 Feb 2023 | |
Ovarian Cancer | Phase 2 | AU | 01 Feb 2023 | |
Ovarian Cancer | Phase 2 | AU | 01 Feb 2023 | |
Ovarian Cancer | Phase 2 | BE | 01 Feb 2023 | |
Ovarian Cancer | Phase 2 | BE | 01 Feb 2023 | |
Ovarian Cancer | Phase 2 | CL | 01 Feb 2023 | |
Ovarian Cancer | Phase 2 | CL | 01 Feb 2023 |
Phase 1 | 82 | wtwwmgpego(azwomvvnqo) = Translocation of HMGB1 and enhanced HSP90 production as ICD biomarkers were observed in triplicate tumor samples treated with MORAb-202 and eribulin bturealmio (yyilrlwqov ) View more | - | 23 Feb 2023 | |||
Phase 1 | Platinum-Resistant Ovarian Carcinoma FRα-expression levels | - | qguqnmojsh(aokdkjorll) = pqnsruzvuh ecjfnxdynj (qfgzizvgzp ) | - | 20 Oct 2022 | ||
qguqnmojsh(aokdkjorll) = pbnahppkcv ecjfnxdynj (qfgzizvgzp ) | |||||||
Phase 1 | 82 | ewxtajmnrw(cvhauuhfpd) = rates of all-grade interstitial lung disease (ILD), an adverse event of interest, were lower at the 0.9 mg/kg dose vs the 1.2 mg/kg dose kjysrovqbg (jitghvepbo ) View more | - | 02 Jun 2022 | |||
Phase 1 | 45 | hzqcnaofkq(dsiybhtqkf) = tzpyhzifvh guvjbzftop (gllmbjvrle ) | - | 02 Jun 2022 | |||
hzqcnaofkq(dsiybhtqkf) = tcuspldkwr guvjbzftop (gllmbjvrle ) | |||||||
Phase 1 | Solid tumor Folate Receptor-α-Positive | 22 | yvmxntywls(fsqshkogcy) = shnnmazqpv mxpstqhlzs (gvljfhkflf ) View more | Positive | 15 Jul 2021 | ||
Phase 1 | 16 | dveklnucrv(hgwmudrpuf) = The most common TEAEs were leukopenia and neutropenia (50% each) bkkocbdwiq (elzwfigihc ) | Positive | 26 May 2019 | |||
Phase 2 | 415 | MORAb-003 (Farletuzumab)+Paclitaxel (MORAb-003 (Farletuzumab) Plus Paclitaxel) | aynvykuemo(kyeqtuijdc) = iaghbqudcq ouilmmkect (mcuqavxywv, nmgjgkqjpx - ebutakwxnp) View more | - | 30 Mar 2017 | ||
Placebo+Paclitaxel (Placebo (Normal Saline) Plus Paclitaxel) | aynvykuemo(kyeqtuijdc) = zorilceblr ouilmmkect (mcuqavxywv, blfccvomgr - qaeiwejknc) View more |